Charm Therapeutics founder Laksh Aithani is out as CEO
The London biotech Charm Therapeutics is looking for a new top executive to replace founding CEO Laksh Aithani, Endpoints News has learned. Aithani co-founded the startup in 2021 at the age of 23 along...
View ArticleEli Lilly reports Phase 3 trial win for oral GLP-1 in diabetes
Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary endpoint of lowering A1C by ...
View ArticleBigHat inks Eli Lilly deal for AI antibody research, extends Series B
BigHat Biosciences has added another pharma partner and more cash to its balance sheet as the antibody specialist prepares to enter the clinic next year. The Bay Area startup will announce a research...
View ArticleSarepta loses CMO to RNA editing upstart; Another wave of personnel moves at...
→ Jacob Elkins has left Sarepta to take the CMO job at AIRNA, the RNA editing shop that disclosed a $155 million Series B earlier this month. The ...
View ArticleNetherlands pours $1.5B into biotech in pursuit of global leadership ambitions
The Dutch government is committing €1.3 billion ($1.5 billion) to support biotech as part of a broader raft of measures designed to make the Netherlands a global leader in the sector by 2040. The...
View ArticleUnitedHealth reports disappointing earnings due to Medicare costs
UnitedHealth Group reported disappointing first-quarter earnings and cut its financial guidance, hit by high costs in its Medicare Advantage business. Though the insurer did not see the same with its...
View ArticleBayer opens $44M US expansion; Meribel CDMO launches in Europe
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bayer has opened its $44 million 70,000-square-foot expansion at its...
View ArticleSanofi to pay $125M upfront for two immunology drugs from Earendil Labs
Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory bowel diseases. Sanofi will give $125 million upfront to Earendil Labs for the...
View ArticleWhat it took for Walgreens to go private
This week, Walgreens revealed how its take-private deal came together. Here are some of the biggest takeaways from the filing: There weren't a ton of options for Walgreens ...
View ArticleUS drugs rely heavily on ingredients made overseas — report
Roughly 85% of the brand-name drugs prescribed in the US rely on ingredients sourced from other countries, according to a new report issued ahead of the Trump administration’s expected tariffs on the...
View ArticleRoche discontinues low dose in Huntington’s trial
Roche is stopping patients on the low dose of its experimental Huntington’s drug tominersen, and will be transitioning them to the high dose following recommendations by an independent data monitoring...
View ArticleCMS would absorb 340B drug discount program under leaked HHS proposal
The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed by Endpoints News. The 64-page document, first reported on ...
View ArticleGSK's myeloma drug Blenrep wins authorization from UK regulators
The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the drug’s first approval worldwide since it was pulled from the US and other...
View ArticleChina-based VelaVigo inks its second US biotech deal
A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign of the industry's flourishing wave of China-to-US drug development...
View ArticleTrump’s executive order on drug pricing; Pfizer drops oral obesity drug; Seed...
Happy Saturday and welcome back to Endpoints Weekly. It was a short week for us with Good Friday this week, but we’re still chock full of news to recap for you. It was another busy ...
View ArticleFDA approves Dupixent for hives, rejects new Eylea dosing schedule
The FDA made two decisions on Regeneron’s best-selling drugs Friday, handing down one approval and one rejection. The approval came for Dupixent, the megablockbuster Regeneron develops and sells with...
View ArticleRoivant brings rare disease program closer as Immunovant CEO retires
Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its drugs to the FDA despite a Phase 3 win. The biopharma company will move to ...
View ArticleTrodelvy and Keytruda combo succeeds in Phase 3 breast cancer study
Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in a key study of an aggressive form of breast cancer. Gilead announced Monday...
View ArticleChina biotech startup HuidaGene uses CRISPR in brain for rare ailment
Late last year, doctors injected an experimental CRISPR therapy into the brain of a 9-year-old boy with a rare neurodevelopmental condition that can cause intellectual disability, movement problems and...
View ArticleAlvogen unit appeals court loss in bid to market Xifaxan generic
Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch Health's Xifaxan to market, the company said. On Friday, its subsidiary Norwich...
View Article